NetraMark Delivers Transformational Quarter Of Execution

Core Insights - NetraMark Holdings Inc. has made significant progress in commercial execution, regulatory engagement, and scientific validation, strengthening its growth trajectory in AI-driven clinical trial optimization [1][2] Group 1: Contract Backlog and Financial Outlook - The contract backlog for NetraMark increased to approximately C$2.5 million, driven by new project commitments and commercial momentum, with a target of reaching C$8–$10 million by mid-2026 [2][4] - The company is experiencing growing commercial traction and expanding channel partnerships, which support its financial outlook [4] Group 2: Regulatory Engagement - NetraMark completed a Critical Path Innovation Meeting (CPIM) with the FDA, receiving feedback on its NetraAI platform and its application in clinical trial design [2] - The FDA discussed considerations for identifying responder-enriched subgroups while maintaining control of Type I error, aligning with FDA enrichment guidance [2] Group 3: Scientific Validation - A scientific study on NetraAI was accepted for publication in npj Digital Medicine, demonstrating its ability to identify clinically meaningful subgroups in a Phase II depression trial [2] - The acceptance by a high-impact journal provides third-party validation of NetraMark's scientific approach [2] Group 4: Strategic Collaborations - NetraMark secured an Ontario Research Fund – Research Excellence Award in collaboration with the Centre for Addiction and Mental Health (CAMH), focusing on analyzing genetic and epigenetic data in psychiatric disorders [2] - This collaboration aims to enhance NetraAI's capabilities in identifying explainable patient subpopulations [2]